ABOUT
precision oncology consulting
Our vision is to enable precision oncology by supporting biotech, pharma, academic centers, diagnostic and therapeutic companies focused on bringing next generation molecular solutions to market and thereby improving cancer patient outcomes.
Precision Oncology Consulting offers an integrated suite of services supporting biotech, pharma, academic centers, diagnostic and therapeutic companies focused on bringing next generation molecular solutions to market and thereby improving patient outcomes.
We have a significant and impressive set of capabilities and resources related to oncology research and collaboration. Our experience in establishing international expert networks, evidence-generating studies and scientific collaborations provides great insight to advancing the field of precision oncology.
With over 18 years of international diagnostic and life science experience, we can support the following oncology technologies and applications:
Services
TEAM
SVETLANA NIKIC, PhD
Founder
Svetlana has spent 18 years within international diagnostic and life sciences and has worked for leading companies within diagnostics and genomics such as Roche Diagnostics, Illumina and more recently C2i Genomics.
Over the years, Svetlana was involved in collaborations and initiatives related to clinical implementation of innovative molecular methods. More specifically, she has worked on the development of the
market for the adoption of genomics-based approaches such as whole-genome and transcriptome sequencing, as well as MRD within oncology routine testing.
Svetlana’s successful track record includes the creation of an international oncology expert network which had as a goal to drive the clinical implementation and adoption of WGS. More specifically, Svetlana made a significant contribution in supporting Swedish clinicians in launching a first and only national initiative aiming towards introduction of WGS and whole-transcriptome analysis into standard of care for all acute myeloid leukamia (AML) and acute lymphoblastic leukemia (ALL) patients across Sweden.
Svetlana holds a MSc in Biochemistry from University of Copenhagen, PhD in molecular biology from Imperial College in London, has done Master in Marketing Management at ESADE Business School, and is currently undertaking Harvard Medical School courses for professionals (HMX Pro), on Clinical Drug Development and Pharmacology.
PRICING
testimonials
HANS VAN SNELLENBERG
Director at Hartwig Medical Foundation The Netherlands
RICHARD ROSENQUIST BRANDELL
Professor of Clinical Genetics - Karolinska Institutet Sweden